ViewsML is a deeptech company in health revolutionizing precision medicine and diagnostics through virtual biomarkers.

Through this partnership with the Department of Pathology and Laboratory Medicine, Dartmouth Health (DH), ViewsML will have access to extensive tissue repository, digital pathology systems, and wet lab infrastructure to further develop virtual biomarkers and diagnostic solutions.

“This collaboration is pivotal, DH’s prestigious reputation as a leader in patient care, research, and education, coupled with its forward-looking adoption of digital pathology, aligns perfectly with our vision. Together, we will redefine AI’s role in biomarker virtualization, staining, and diagnostics to enhance patient outcomes.” – Dr. Kenneth To, CEO of ViewsML

This collaboration focuses on developing ViewsML’s virtual IHC staining platform, which reduces dependencies on traditional, physical antibodies and immunostaining and improves processing time. DH’s resources will allow ViewsML to create virtual biomarker panels that have the potential to revolutionize spatial proteomics, enhance patient selection for clinical trials, and improve risk stratification for clinical diagnostics and precision medicine.

“ViewsML’s transformative AI platform represents a leap forward for both research and clinical care. We are thrilled to collaborate with ViewsML to harness AI’s full potential in creating the next generation of precision diagnostics.” – Dr. Arief Suriawinata, Interim Chair for the Department of Pathology and Laboratory Medicine at DH.

Read the full article to learn more about ViewsML’s partnership: https://www.rochesterfirst.com/business/press-releases/ein-presswire/800970123/viewsml-and-dartmouth-health-partner-to-advance-ai-driven-virtual-biomarkers-and-diagnostics/